FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366824242> ?p ?o ?g. }

• W4366824242 endingPage "12" @default.
• W4366824242 startingPage "1" @default.
• W4366824242 abstract "Nimotuzumab exerts its antitumor effect (mainly antiproliferative, proapoptotic, and antiangiogenic) by blocking the epidermal growth factor receptor overexpressing between 30 and 95% in pancreatic tumors cells.A prospective, nonrandomized, uncontrolled, open-label, and multicenter clinical trial was conducted to evaluate the safety and effectiveness of nimotuzumab combined with gemcitabine as first-line treatment in unresectable locally advanced or metastatic pancreatic tumors in a real-world condition. Adverse events, their intensity, severity, and causality were determined using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.0). Median overall survival, median progression-free survival, and 1- and 2-year survival rates were determined by using the Kaplan-Meier.69 patients were included. The proportion of related serious adverse events was 1.2%. The most frequent adverse events were nausea (10%), anemia (8%), and abdominal pain (8%). Objective response was achieved in 18.5% of the patients and disease control in 43.1%. Patients with locally advanced disease achieved a median overall survival of 16.36 months (95% CI; 14.35-18.38); 1- and 2-year survival rates of 72.2 and 29.2 months, respectively; a median progression-free survival of 9.6 months (95% CI; 4.91-14.20); and a 1-year progression-free survival rate of 39%. Patients with metastatic disease achieved a median survival of 6.23 months (95% CI; 4.32-8.13); 1- and 2-year survival rates of 18.1 and 3.0 months, respectively; a median progression-free survival of 7.6 months (95% CI; 6.08-9.90); and 1- and 2-year PFS rates of 20.5 and 5.1 months, respectively.Nimotuzumab combined with gemcitabine represents a safe and effective first-line treatment option for patients with advanced pancreatic adenocarcinoma in real-world conditions. Survival benefits were increased in those patients who received 8 or more doses of nimotuzumab. This trial is registered with RPCEC00000245 in the Cuban Registry of Clinical Trials, part of the World Health Organization's International Clinical Trials Registry Platform (ICTRP)." @default.
• W4366824242 created "2023-04-25" @default.
• W4366824242 creator A5001445190 @default.
• W4366824242 creator A5007666342 @default.
• W4366824242 creator A5011906204 @default.
• W4366824242 creator A5018657810 @default.
• W4366824242 creator A5033376870 @default.
• W4366824242 creator A5035884399 @default.
• W4366824242 creator A5046821274 @default.
• W4366824242 creator A5052103835 @default.
• W4366824242 creator A5061517364 @default.
• W4366824242 creator A5063695803 @default.
• W4366824242 creator A5066162216 @default.
• W4366824242 creator A5066645969 @default.
• W4366824242 creator A5070361689 @default.
• W4366824242 creator A5072032410 @default.
• W4366824242 creator A5075154201 @default.
• W4366824242 creator A5084967864 @default.
• W4366824242 date "2023-04-24" @default.
• W4366824242 modified "2023-10-01" @default.
• W4366824242 title "Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma" @default.
• W4366824242 cites W2011513069 @default.
• W4366824242 cites W2031915840 @default.
• W4366824242 cites W2037612567 @default.
• W4366824242 cites W2060819673 @default.
• W4366824242 cites W2074885018 @default.
• W4366824242 cites W2094037194 @default.
• W4366824242 cites W2094506831 @default.
• W4366824242 cites W2144025124 @default.
• W4366824242 cites W2151253787 @default.
• W4366824242 cites W2158134441 @default.
• W4366824242 cites W2165480504 @default.
• W4366824242 cites W2165879808 @default.
• W4366824242 cites W2217975404 @default.
• W4366824242 cites W2340049292 @default.
• W4366824242 cites W2346921980 @default.
• W4366824242 cites W2533198601 @default.
• W4366824242 cites W2588870789 @default.
• W4366824242 cites W266876247 @default.
• W4366824242 cites W2724558203 @default.
• W4366824242 cites W2791015748 @default.
• W4366824242 cites W2799777523 @default.
• W4366824242 cites W2898368508 @default.
• W4366824242 cites W2904258450 @default.
• W4366824242 cites W3001114988 @default.
• W4366824242 cites W3091421761 @default.
• W4366824242 cites W3128646645 @default.
• W4366824242 cites W3132809852 @default.
• W4366824242 cites W3153075376 @default.
• W4366824242 cites W3169321271 @default.
• W4366824242 cites W4206323393 @default.
• W4366824242 cites W4255768024 @default.
• W4366824242 cites W4280609979 @default.
• W4366824242 cites W4290963581 @default.
• W4366824242 doi "https://doi.org/10.1155/2023/1496072" @default.
• W4366824242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37152586" @default.
• W4366824242 hasPublicationYear "2023" @default.
• W4366824242 type Work @default.
• W4366824242 citedByCount "0" @default.
• W4366824242 crossrefType "journal-article" @default.
• W4366824242 hasAuthorship W4366824242A5001445190 @default.
• W4366824242 hasAuthorship W4366824242A5007666342 @default.
• W4366824242 hasAuthorship W4366824242A5011906204 @default.
• W4366824242 hasAuthorship W4366824242A5018657810 @default.
• W4366824242 hasAuthorship W4366824242A5033376870 @default.
• W4366824242 hasAuthorship W4366824242A5035884399 @default.
• W4366824242 hasAuthorship W4366824242A5046821274 @default.
• W4366824242 hasAuthorship W4366824242A5052103835 @default.
• W4366824242 hasAuthorship W4366824242A5061517364 @default.
• W4366824242 hasAuthorship W4366824242A5063695803 @default.
• W4366824242 hasAuthorship W4366824242A5066162216 @default.
• W4366824242 hasAuthorship W4366824242A5066645969 @default.
• W4366824242 hasAuthorship W4366824242A5070361689 @default.
• W4366824242 hasAuthorship W4366824242A5072032410 @default.
• W4366824242 hasAuthorship W4366824242A5075154201 @default.
• W4366824242 hasAuthorship W4366824242A5084967864 @default.
• W4366824242 hasBestOaLocation W43668242421 @default.
• W4366824242 hasConcept C121608353 @default.
• W4366824242 hasConcept C126322002 @default.
• W4366824242 hasConcept C141071460 @default.
• W4366824242 hasConcept C143998085 @default.
• W4366824242 hasConcept C197934379 @default.
• W4366824242 hasConcept C2776283816 @default.
• W4366824242 hasConcept C2776694085 @default.
• W4366824242 hasConcept C2777793932 @default.
• W4366824242 hasConcept C2780258809 @default.
• W4366824242 hasConcept C2780739268 @default.
• W4366824242 hasConcept C71924100 @default.
• W4366824242 hasConcept C90924648 @default.
• W4366824242 hasConceptScore W4366824242C121608353 @default.
• W4366824242 hasConceptScore W4366824242C126322002 @default.
• W4366824242 hasConceptScore W4366824242C141071460 @default.
• W4366824242 hasConceptScore W4366824242C143998085 @default.
• W4366824242 hasConceptScore W4366824242C197934379 @default.
• W4366824242 hasConceptScore W4366824242C2776283816 @default.
• W4366824242 hasConceptScore W4366824242C2776694085 @default.
• W4366824242 hasConceptScore W4366824242C2777793932 @default.
• W4366824242 hasConceptScore W4366824242C2780258809 @default.

• next